We are on a mission to radically improve disease diagnoses and treatments, helping people live longer, healthier lives.
With PET, the barriers to better imaging are largely the result of basic limitations in chemistry. Leveraging a breakthrough in alkali metal catalysis, Fuzionaire Dx is working to radically improve the scope, safety, use, and cost of PET imaging.
Fuzionaire Dx is a radiopharmaceutical company. Our radiolabeling platform aims to unlock the power of PET to help detect and treat any disease and improve the drug discovery process.
We make it possible to rapidly produce a broad range of fluorine-18 radiopharmaceuticals based on a single, catalyst-driven, disease-agnostic platform. Our technology offers researchers and clinicians a new strategy to detect, localize, diagnose, and monitor more diseases, earlier, and with unprecedented precision.
The platform also has the potential to become a unique tool for drugmakers, providing critical in vivo pharmacological data earlier in the drug discovery process.
As a team of chemists, biophysicists, molecular scientists, and entrepreneurs, our mission is to unlock the power of PET to improve the human condition.
Fuzionaire is led by co-founders Nick Slavin (CEO), Anton Toutov, PhD (CSO), Nova Spivack, and a close-knit team of world-class experts advising the company.
Nick SlavinCo-Founder and CEOFuzionaire
Mr. Slavin is the founder of EES Ventures, a venture capital firm focusing on seed-stage technologies out of universities, and founder and chairman of the Slavin Family Foundation, which operates a fellowship supporting world-changing student entrepreneurs. He is also a co-founder with Mr. Spivack of the Arch Mission Foundation, a nonprofit creating multiple redundant repositories of human knowledge in space, which created the first permanent library in solar orbit in February 2018 as part of SpaceX’s Falcon Heavy test launch. Previously, Mr. Slavin spent seven years as a corporate attorney at Norton Rose Fulbright and Skadden Arps, at the time the #1 ranked corporate law firm by Corporate Board Member magazine for 13 consecutive years. Mr. Slavin is an advisor at the Texas Medical Center Innovation Institute and an investor in and advisor to a number of life science, medical device, energy, and digital technology companies. He holds a BA magna cum laude from Yale, where he graduated at 19, and a JD from Harvard Law School.
Anton Toutov PhDCo-Founder and CSOFuzionaire
Dr. Toutov holds a PhD in organic chemistry from Caltech in the laboratory of Nobel Laureate Robert H. Grubbs, where he held Dow-Resnick, NSERC, and Bristol-Myers Squibb fellowships. Dr. Toutov collectively has over 40 scholarly articles and patent grants and applications to his name spanning the fields of chemical synthesis, clean energy, and drug discovery. Among them is the discovery of a new form of catalysis, which was first published in Nature and was later presented to general audiences in the documentary film Element 19. He is the recipient of the 2016 Demetriades Caltech Thesis Prize, the 2015 Alfred Bader Award for Student Innovation (Sigma-Aldrich Corporation), the 2014 Dow Chemical Sustainability Challenge Grand Prize, and the 2014 Milliken & Co. “Deep Science” award, among others. Dr. Toutov also serves as senior technical advisor to the Gates Foundation-backed Medicines for All Institute, improving access to affordable, high-quality medicines.
Mr. Spivack is a serial entrepreneur, technology futurist, and co-founder of the in house incubator of Stanford Research Institute (SRI) and Sarnoff Laboratories, which launched SIRI (acquired by Apple). He is the founder and CEO of the early stage science and technology incubator, Magical, and is co-founder and chairman of the Arch Mission Foundation. Previously, Mr. Spivack was CEO of Bottlenose, a leader in real-time data analytics. He founded Radar Networks in 2003, business incubator Lucid Ventures in 2001, and in 1994 he co-founded EarthWeb, Inc., one of the first web start-ups (record-breaking IPO in 1998) and spinout Dice.com (IPO in 2007). He is also a co-founder or early investor in The Daily Dot, Klout (acquired by Lithium), and a number of applied and life science companies including Space Adventures and Cambrian Genomics. Mr. Spivack is an inventor on nearly 100 granted and pending patents.
Fred Chin PhDAdvisory BoardStanford
Dr. Chin is Head of Cyclotron Radiochemistry and Assistant Professor of Radiology at Stanford University School of Medicine, where he researches and develops novel imaging agents and therapeutics with a focus on PET imaging. Closely linked with Stanford Health Care, Dr. Chin’s group provides more than 20 doses of 18F-FDG daily for standard-of-care PET imaging, and has brought or is in the process of bringing more than a dozen other tracers to the clinic. His group is involved in the arc of drug development, from research on the benchtop to translational first-in-human clinical studies, primarily using radiolabeled 18F and 11C tracers. Much of his interest lies in developing tracers to image the mysterious diseases of the brain (e.g., pain, addiction, Parkinson’s disease, Alzheimer’s disease, glioblastoma) or other cancers.
Dennis Liotta PhDAdvisory BoardEmory
Dr. Liotta is the Samuel Candler Dobbs Professor of Chemistry at Emory University and Executive Director of the Emory Institute for Drug Development. Through his discoveries, Dr. Liotta has helped to transform HIV/AIDS from a death sentence to a chronic infection. Over 90% of all of the HIV-infected persons in the United States have taken one of the drugs he invented. Dr. Liotta is an inventor on 75 issued US patents, many of which cover the antiviral and anticancer drugs and drug candidates he has discovered. He is the co-founder of numerous companies, two of which were acquired by Gilead Pharmaceuticals. He is recognized as one of the premier discoverers of novel therapeutics in the United States, having been an inventor of 10 FDA approved therapeutics including Epivir, Combivir, Trizivir, Epzicom, Epivir-HBV, Emtriva, Truvada, Atripla, Complera and Stribid.
Jennifer Murphy PhDAdvisory BoardUCLA
Dr. Murphy is an Assistant Professor in the Department of Molecular and Medical Pharmacology at the Crump Institute for Molecular Imaging, and is a member of the Jonsson Comprehensive Cancer Center at UCLA. Previously, she was a visiting scholar in Tobias Ritter’s research laboratory at Harvard, and a Scholar in Oncologic Molecular Imaging (SOMI) postdoctoral fellow in the Ahmanson Translational Imaging Division at the David Geffen School of Medicine at UCLA. She is the recipient of a UCLA SPORE in Prostate Cancer Career Development Award, a UCLA Center for In Vivo Imaging in Cancer Biology Career Development Award, and an NIH Chemistry-Biology Interface Fellowship. Prof. Murphy received her Ph.D. from UCLA under the direction of Michael E. Jung.
Douglas Scherr MDAdvisory BoardWeill Cornell
Dr. Scherr is a Professor of Urology and the Clinical Director of Urologic Oncology at the Weill Medical College of Cornell University. Dr. Scherr’s clinical focus is the treatment of urologic malignancies – in particular, the treatment of prostate cancer, bladder cancer, kidney cancer, and testicular cancers, as well as genitourinary and retroperitoneal sarcomas. He was the first physician at Cornell to perform a robotic prostatectomy, and travels nationally and internationally teaching the procedure to urologic surgeons. He has been active in the development of optical coherence tomography and its application to urologic imaging, and patented and developed the concept of “multiphoton endoscopy,” which utilizes high-speed laser energy to create high quality microscopic images of human tissue.
Kristin Swanson PhDAdvisory BoardMayo Clinic
Dr. Swanson is a Professor and Vice Chair for Research in the Department of Neurologic Surgery at Mayo Clinic. She is also Director of the Mathematical Neuro-Oncology Laboratory and Co-Director of the Precision Neurotherapeutics Innovation Program at Mayo Clinic. Dr. Swanson is a quantitative cancer researcher (mathematical oncologist) whose research lab has pioneered the burgeoning field of Mathematical Neuro-Oncology, developing patient-specific mathematical models of glioma to assess and predict disease course and optimize treatment. The lab works with clinical and research teams at Mayo Clinic to bring these innovations to the clinic while identifying new predictive models. Dr. Swanson’s research has been supported through funding by the NIH, numerous foundations, the James D. Murray Endowed Chair at the University of Washington, TGen, and the Mayo Clinic.
As we enter the world of precision medicine, Fuzionaire Diagnostics provides technology that could help track and image cancers in an unprecedented way, which will ultimately allow for many novel approaches in cancer therapeutics.
Expanding the bounds of how we diagnose, study, and treat disease
We are continuously exploring additional clinical applications of our radiolabeling platform.
- Our heterocyclic chemistry enables radiopharmaceuticals that combine diagnostic and therapeutic approaches
- Accelerating radiopharmaceutical discovery through combinatorial synthesis of radiotracer libraries
- Pioneering new engineering solutions that combine flow chemistry, synthesis electrification, and automation
Get in touch
If you are interested in learning more about our radiolabeling platform, we want to hear from you.Contact